- Featured Product
- KD/KO Validated
MCL1 Monoclonal antibody, PBS Only (Capture)
MCL1 Monoclonal Antibody for WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA
Host / Isotype
Mouse / IgG2b
Reactivity
human
Applications
WB, IHC, IF/ICC, Cytometric bead array, Indirect ELISA
Conjugate
Unconjugated
CloneNo.
1E3C2
Cat no : 66026-1-PBS
Synonyms
Validation Data Gallery
Product Information
66026-1-PBS targets MCL1 as part of a matched antibody pair:
MP50655-1: 66026-1-PBS capture and 66026-2-PBS detection (validated in Cytometric bead array)
Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
Tested Reactivity | human |
Host / Isotype | Mouse / IgG2b |
Class | Monoclonal |
Type | Antibody |
Immunogen | MCL1 fusion protein Ag10609 |
Full Name | myeloid cell leukemia sequence 1 (BCL2-related) |
Calculated Molecular Weight | 350 aa, 37 kDa |
Observed Molecular Weight | 35 kDa |
GenBank Accession Number | BC107735 |
Gene Symbol | MCL1 |
Gene ID (NCBI) | 4170 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS Only |
Storage Conditions | Store at -80°C. |
Background Information
MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target.